Search
Urea C-13
go.drugbank.com/drugs/DB09510ApprovedInvestigationalRadiolabelled urea is available in two forms as 13C and 14C. … It is currently used for the Urea Breath Test (UBT) and is available as a rapid diagnostic test (marketed as Pranactin-Citric) for the detection of Helicobacter pylori infections.
Sodium carbonate
go.drugbank.com/drugs/DB09460ApprovedWithdrawnAs a strong base, sodium hydroxide neutralizes gastric acid thereby acting as an antacid.
Anileridine
go.drugbank.com/drugs/DB00913ApprovedIllicitWithdrawnAnileridine is a synthetic opioid and strong analgesic medication. It is a narcotic pain reliever used to treat moderate to severe pain. Narcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effe...
Oritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigationalIt boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy. … It was developed by The Medicines Company (acquired by Novartis).
Dasiglucagon
go.drugbank.com/drugs/DB15226ApprovedIt is available as a subcutaneous injection marketed as ZEGALOGUE.
Protein-arginine deiminase type-4
go.drugbank.com/bio_entities/BE0001092TargetHumansCatalyzes the citrullination/deimination of arginine residues of proteins such as histones, thereby playing a key role in histone code and regulation of stem cell maintenance (PubMed:15339660, PubMed:15345777, PubMed:16567635, PubMed:191...
Synonyms: HL-60 PADEntacapone
go.drugbank.com/drugs/DB00494ApprovedInvestigationalWhen administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration
Polycarbophil
go.drugbank.com/drugs/DB09311ApprovedWithdrawnLess gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali.
Cannabidivarin
go.drugbank.com/drugs/DB14050InvestigationalIn October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome [L2952] and again in February 2018 for treatment of Fragile X Syndrome [L2951]. … Cannabidivarin is being actively developed by GW Pharmaceuticals as the experimental compound GWP42006 as it has "shown the ability to treat seizures in pre-clinical models of epilepsy with significantly
Nintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[L8453,L8459] It was first approved for use in the United States in 2014. … such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.